Targeting WEE1 in an effort to enhance therapy in PDA cells is especially thought provoking in light of our recent study that DNA damaging agents can rapidly and potently induce an HuR-dependent WEE1 upregulation18. The gene discussed is ELAVL1; the disease is Patent ductus arteriosus.